Literature DB >> 8607630

Drugs associated with bullous pemphigoid. A case-control study.

S Bastuji-Garin1, P Joly, C Picard-Dahan, P Bernard, L Vaillant, C Pauwels, V Salagnac, C Lok, J C Roujeau.   

Abstract

UNLABELLED: Bullous pemphigoid is the most frequent autoimmune blistering disease. It occurs in the elderly. The cause of this disease is unknown, but cases of bullous pemphigoid have been occasionally attributed to drug therapy. We conducted a multicenter prospective case-control study looking at the drugs used on a long-term basis before the onset of the disease in 116 incident cases of bullous pemphigoid and 216 control patients with malignant or benign skin tumors.
RESULTS: Case patients and control patients received many drugs on a long-term basis (mean +/-SD, 4.4+/-3.2 and 4.4+/-2.7 years respectively). Two classes of drugs, neuroleptics and diuretics, were used more frequently by case patients than control patients. Neuroleptics were used by 15.5% of case patients and 8.3% of control patients (adjusted odds ratios; 1.9; 95% confidence interval, 0.95 to 3.8). Diuretics were used by 36.2% of case patients and 24.5% of control patients (adjusted odds ratios, 1.8; 95% confidence interval, 1.1 to 2.9). Among neuroleptics, no specific drug emerged. The association with diuretics was only linked to aldosterone antagonists, which were taken by 12.9% of case patients and 4.6% of control patients (adjusted odds ratios, 3.1; 95% confidence interval, 1.4 to 7.1).
CONCLUSIONS: These results suggest that some drug therapies may be a risk factor for bullous pemphigoid. The cause of this association should be further investigated.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8607630

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  26 in total

Review 1.  Bullous pemphigoid: from bench to bedside.

Authors:  Scott R A Walsh; David Hogg; P Régine Mydlarski
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 2.  Autoimmune Subepidermal Bullous Diseases of the Skin and Mucosae: Clinical Features, Diagnosis, and Management.

Authors:  Kyle T Amber; Dedee F Murrell; Enno Schmidt; Pascal Joly; Luca Borradori
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 8.667

Review 3.  [Bullous pemphigoid: diagnosis and therapy].

Authors:  Andrea Kneisel; Michael Hertl
Journal:  Wien Med Wochenschr       Date:  2014-07-31

Review 4.  Thyroid diseases and skin autoimmunity.

Authors:  Enke Baldini; Teresa Odorisio; Chiara Tuccilli; Severino Persechino; Salvatore Sorrenti; Antonio Catania; Daniele Pironi; Giovanni Carbotta; Laura Giacomelli; Stefano Arcieri; Massimo Vergine; Massimo Monti; Salvatore Ulisse
Journal:  Rev Endocr Metab Disord       Date:  2018-12       Impact factor: 6.514

Review 5.  Subepidermal autoimmune bullous diseases: overview, epidemiology, and associations.

Authors:  Khalaf Kridin
Journal:  Immunol Res       Date:  2018-02       Impact factor: 2.829

6.  Association Between Medication Use and Bullous Pemphigoid: A Systematic Review and Meta-analysis.

Authors:  Sian-De Liu; Wei-Ti Chen; Ching-Chi Chi
Journal:  JAMA Dermatol       Date:  2020-08-01       Impact factor: 10.282

Review 7.  Adverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch.

Authors:  Brian A Baldo; Nghia H Pham
Journal:  Cancer Metastasis Rev       Date:  2013-12       Impact factor: 9.264

8.  Bullous pemphigoid associated with dipeptidyl peptidase IV inhibitors. A case report and review of literature.

Authors:  Amy Attaway; Tracey L Mersfelder; Sakshi Vaishnav; Joanne K Baker
Journal:  J Dermatol Case Rep       Date:  2014-03-31

Review 9.  Drug-induced skin, nail and hair disorders.

Authors:  Laurence Valeyrie-Allanore; Bruno Sassolas; Jean-Claude Roujeau
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

Review 10.  Cutaneous Drug Reactions in the Elderly.

Authors:  James W S Young; Neil H Shear
Journal:  Drugs Aging       Date:  2017-09       Impact factor: 4.271

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.